Botulinum toxin type A is a prescription medical product that temporarily reduces neuromuscular transmission in selected muscles. For aesthetic use, assessment combines the authorized product information, facial anatomy, muscle activity, medical history, and the person’s expectations. Dose units of different products must not be considered equivalent.
Does botulinum toxin cause “addiction”?Studies of aesthetic botulinum toxin have evaluated efficacy, safety, and repeated treatment; current clinical data do not establish evidence that equates the procedure with pharmacological dependence in the sense of a substance-use disorder. Wanting the previous appearance again as the effect fades, or requesting another appointment, is not by itself a diagnosis of medical dependence.
Nevertheless, intense appearance-related distress, impaired daily functioning, increasingly frequent requests for procedures, or unrealistic expectations require a separate clinical assessment. Research suggests that validated screening tools for body-image disorders may be useful in aesthetic settings; screening does not establish a diagnosis, and referral to a mental-health professional may be appropriate.
Will facial expression disappear completely?The expected action of botulinum toxin is a temporary reduction in the activity of the injected muscle. The degree of change in facial expression varies with the product, dose, injection point, muscle strength, facial anatomy, and intended outcome. It cannot be guaranteed that the result will “always look natural” or that facial expression will “never be affected.”
Unwanted effects such as excessive muscle weakness, asymmetry, or brow or eyelid droop can occur. Although most events reported in a systematic review of upper-face treatments were mild and temporary, definitions and reporting quality differed across studies. Risks should therefore be discussed individually before treatment.
When does the effect begin, and how long does it last?Onset and duration vary with the product, treatment area, dose, and individual response. Studies have followed outcomes over days and months; one duration should not be treated as universal. Retreatment is planned by considering return of muscle movement, the previous response, examination findings, and the official information for the relevant product—not the calendar alone.
Clinical studies of repeated treatment have reported acceptable tolerability for most participants; this does not guarantee the same outcome for everyone or justify unlimited treatment frequency.
Are botulinum toxin and biostimulators the same?No. Botulinum toxin acts on neuromuscular transmission and aims to reduce muscle activity, particularly in dynamic lines that become more visible with expression. Injectable biostimulators such as PLLA or calcium hydroxylapatite are assessed in relation to tissue characteristics, volume, and collagen response; they are not products that reduce muscle movement.
Although systematic reviews of biostimulators report favourable findings, products, techniques, and measurement methods differ considerably, and some reviews emphasize limited evidence quality. Injection-related risks—including bruising, swelling, tenderness, nodules, infection, and vascular complications—can vary by product and treatment area.
These approaches are not automatically alternatives to, or complements of, one another. Any procedure under consideration is determined during examination from the person’s main concern, anatomy, tissue characteristics, medical history, and accepted risks. Sometimes recommending no procedure is the most appropriate medical decision.
What information should be shared before treatment?* Previous botulinum toxin, filler, or biostimulator procedures and any unexpected effects
* Neuromuscular disorders and any history of difficulty swallowing, speaking, or breathing
* Pregnancy or breastfeeding status and any planned pregnancy
* All prescription and non-prescription medicines, supplements, muscle relaxants, and recently used antibiotics
* Active infection, wound, or skin disease in the treatment area
* The desired change, dissatisfaction with previous procedures, and intense appearance-related concerns
Prescription medicines should not be stopped on one’s own solely to reduce bruising risk. Any medication change should be discussed with the prescribing clinician.
Common effects and situations requiring urgent assessmentPain, redness, swelling, or bruising at the injection site; headache; and temporary muscle weakness may occur. Unexpected asymmetry or brow or eyelid droop should be assessed by the treating physician.
Urgent medical assessment is required if difficulty swallowing, speaking, or breathing; generalized muscle weakness; or rapidly progressing serious symptoms develop. Do not wait for a routine follow-up appointment in these circumstances.
Why do an authorized product and qualified practitioner matter?A licensed, traceable product stored under appropriate conditions, and administration by an authorized physician in a suitable clinical setting, are fundamental safety elements. Products obtained online or from an unclear or counterfeit source can pose serious health risks. Self-injection is not safe.
Clinical information pageYou can review the clinic’s information page on the examination, risk, and follow-up framework for botulinum toxin treatment.
This article provides general information; it is not a diagnosis, individualized medical advice, or a guarantee of results. Suitability and informed consent require an in-person physician assessment.
Last updated: 24 August 2026
References1. Zargaran D, et al. Complications of Cosmetic Botulinum Toxin A Injections to the Upper Face: A Systematic Review and Meta-Analysis. Aesthetic Surgery Journal. 2022;42(5):NP327–NP336. PMID: 35178552. DOI: 10.1093/asj/sjac036.
2. Rubin MG, et al. The efficacy and safety of botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. J Drugs Dermatol. 2009;8(5):439–444. PMID: 19537366.
3. Glogau R, et al. Duration of effect of onabotulinumtoxinA in aesthetic treatment of glabellar lines. Dermatologic Surgery. 2012. PMID: 23106853. DOI: 10.1111/j.1524-4725.2012.02582.x.
4. U.S. Food and Drug Administration. BOTOX Cosmetic Prescribing Information. Revision: 2024.
5. Borab ZM, et al. The emerging role of biostimulators as an adjunct in facial rejuvenation: A systematic review. Br J Plast Surg. 2024. PMID: 38518624. DOI: 10.1016/j.bjps.2024.02.069.
6. Signori R, et al. Efficacy and Safety of Poly-L-Lactic Acid in Facial Aesthetics: A Systematic Review. Polymers. 2024;16(18):2564. PMID: 39339028. DOI: 10.3390/polym16182564.
7. Ribeiro RVE, et al. Evidence-based review: Screening body dysmorphic disorder in aesthetic clinical settings. J Cosmet Dermatol. 2023. PMID: 36847707. DOI: 10.1111/jocd.15685.
This article was prepared for general information by the Dr. Mehmet Yavaş clinic in Serdivan, Sakarya. Dr. Mehmet Yavaş · Arabacıalanı Mah. Mert Sk. No:46 Nurten Şükür İş Merkezi C-4 Kat:2, 54050 Serdivan / Sakarya
